Novo Nordisk’s Ozempic drug gets FDA OK for 2 mg dose to treat Type-2 Diabetes

0
65

By Dominic Chopping


Danish pharmaceutical company Novo Nordisk AS said late Monday that the U.S. Food and Drug Administration has approved a 2.0 milligram dose of its Ozempic drug to treat adults with type 2 diabetes.

Ozempic is now approved in the U.S. at 0.5 milligram, 1.0 milligram and 2.0 milligram doses for the treatment of type 2 diabetes in adults, it added.

In addition, Ozempic is indicated to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease, the company said.

Novo Nordisk expects to launch Ozempic 2.0 milligram in the U.S. in the second quarter of 2022.

Ozempic 2.0 milligram is now approved in the U.S., the EU, Canada and Switzerland.


Write to Dominic Chopping at dominic.chopping@wsj.com


This article was originally published by Marketwatch.com. Read the original article here.

Previous articleGameStop stock rises again, and is on course for the longest win streak in more than a decade
Next article: U.S. official says new sanctions may be placed on Russian industry

LEAVE A REPLY

Please enter your comment!
Please enter your name here